Form 4: Bicara Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Jeremy Bender, a Director of Bicara Therapeutics Inc., received 38,950 shares of common stock on July 28, 2026.
Summary
- Grant/award: acquired 38,950 Stock Option (Right to Buy) on July 28, 2026; holds 38,950 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jeremy Bender — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-28 | Grant/award | Stock Option (Right to Buy) | 38,950 | — | — | 38,950 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-28 | Grant/award (38,950 shares) |
Keywords
insider transaction, Form 4, BCAX, Bicara Therapeutics Inc., neutral, Jeremy Bender
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.